Title:
ANTIBODY PRODRUGS WITH CONSTANT DOMAINS
Document Type and Number:
WIPO Patent Application WO/2023/025156
Kind Code:
A1
Abstract:
Provided are antibody prodrugs that include an immunoglobulin superfamily constant region, such as CH3, or variant coupled to one or more chains of the antibody, optionally through a cleavable linker. It is discovered that the constant domain and variants serve as effective and safe masking moieties that inhibit the activity of the antibody. Once removed from the antibody, such as by a corresponding enzyme at a target treatment tissue, the antibody prodrug releases the active antibody. In tissues where no such enzyme is present, the antibody prodrug stays inactive, avoiding adverse effects in such tissues.
Inventors:
FANG LEI (CN)
SHEN HAO (CN)
ZENG PENG (CN)
SHEN HAO (CN)
ZENG PENG (CN)
Application Number:
PCT/CN2022/114310
Publication Date:
March 02, 2023
Filing Date:
August 23, 2022
Export Citation:
Assignee:
CONCEPT TO MEDICINE BIOTECH CO LTD (CN)
International Classes:
C07K16/28; A61K39/00; A61P31/00; A61P35/00; A61P37/00; C07K14/725
Domestic Patent References:
| WO2020246563A1 | 2020-12-10 | |||
| WO2018213335A1 | 2018-11-22 | |||
| WO2020210619A1 | 2020-10-15 | |||
| WO2020216883A1 | 2020-10-29 |
Foreign References:
| US20210155701A1 | 2021-05-27 | |||
| US20190119383A1 | 2019-04-25 |
Other References:
METZ SILKE ET AL: "Bispecific antibody derivatives with restricted binding functionalities that are activated by proteolytic processing.", REDUCED ELIMINATION OF IGG ANTIBODIES BY ENGINEERING THE VARIABLE REGION., vol. 25, no. 10, 1 October 2012 (2012-10-01), pages 571 - 580, XP002770139, ISSN: 1741-0134, DOI: 10.1093/protein/gzs064
Attorney, Agent or Firm:
SHANGHAI BESHINING LAW OFFICE (CN)
Download PDF: